is all in $AAPL $TSLA and $PMCB
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
what's interesting is the call gave context to some of the recent moves. TD2 having issues? $PMCB brings in Dr. Sher who has expertise running clinical trials. things moving slowly? bring in Dr. Tong who could get things moving quickly in Chinese trials instead.
no idea honestly. i'm still in $PMCB for the six month time frame. after that I'll reevaluate. we better see some real progress in the coming months.
well said efood!
Great level-headed post!
Go $PMCB
Looking good Pete!
$SGMO is currently rated a HOLD and long term is a BUY. Earnings are at close today.
$OTIC has a book value of $4.96. Amazing share price considering this company is sitting on over $200 million dollars in cash and US Treasuries.
https://www.barchart.com/stocks/quotes/OTIC/profile
https://finance.yahoo.com/quote/OTIC/balance-sheet?p=OTIC
$SGMO Q3 earnings will be announce on October 24th.
"Apple (AAPL) shares were up 1.5% in midday trading after KeyBanc Capital upgraded the stock to Overweight, saying the aggressive move to "subscription-like" phone purchases can offset slowing sales, MarketWatch reports. KeyBanc's base-case price target is $187, which is 17% above a recent price of $159.41."
From Barron's today.
Anyone know how many people are following $PMCB on FB? Seems like the number is higher than I remember.
https://www.facebook.com/pharmacytebiotech/
1,063 Likes
1,099 Followers
13th was short report day, of course the price was moved down. Next date is 10/31. Mark your calendars.
http://www.finra.org/industry/short-interest/short-interest-reporting-due-dates
Not getting rich fast enough via the OTC and weedstocks? Hurry, dump your IRA and 401(k) in Bitcoin:
http://bitcoinira.com/buy-bitcoins/
The email I received about this says "Analyst Predicts Bitcoin Could be Worth $50,000 Soon - Act Now, Before It's Too Late".
A PhD from Janssen attended PMCB's presentation at the Bio conference. You know, when PMCB won the 2017 Pipelines of Promise award
http://convention.bio.org/buzzofbio/
You know, Bio, attended by over 1,100 biotech companies and 16,000 people in the industry.
It's a Red Herring. In the past few weeks we've had Argument from Silence, Shifting the Burden of Proof, False Attribution, Wrong Direction, Appeal to Fear, Ad Hominem...
Really, I mean every fallacy I know has been thrown at us along with the kitchen sink when being critical of $PMCB.
Wow, who would have thought that debate club would come in handy when discussing biotechs...
Share price indicates many, many others believe it's a possibility. $PTOTF has been on Fox News and CNBC since the shooting.
Again, IF the victims sue and IF they win, the casinos' insurance companies are going to force them to do something. I don't see Vegas casinos looking like TSA checkpoints if it can be avoided.
Do you know other tech companies that are offering casinos an alternate weapon detection system?
That was April 30, 2017. On October 1st we had the deadliest shooting in US history, because a casino failed to prevent a nutjob from amassing an arsenal of 23 rifles in his hotel suite.
If you've been following the news closely, it certainly appears the MGM will be sued by the victims' families and by the hundreds of injured. After massive lawsuits, insurance companies force their clients to do whatever they must do prevent the same situation from happening again.
I don't believe every casino in Las Vegas will install metal detectors. That just goes against the entire vibe and atmosphere of Vegas. Instead, $PTOTF's discrete system could be installed at and inside elevators to alert security that someone has weapons.
An elevator is the perfect place to install such a system as it can be locked down and isolated.
IF the US Gov determines that $PTOTF's tech could save lives, I'd expect accelerated approvals for whatever licenses Patriot One needs.
Pancreatic Cancer-Induced Diabetes: A Call To Action by Dr Richard Frank, MD
Oncology Times: October 10, 2017
http://journals.lww.com/oncology-times/Fulltext/2017/10100/Pancreatic_Cancer_Induced_Diabetes__A_Call_To.2.aspx
"Cause or Consequence?
Pancreatic cancer and diabetes are locked in a complicated dance, both pathogenetically and temporally. In the setting of a new pancreatic cancer diagnosis, the timing and course of the diabetes can be divided into three main categories:
long-standing diabetes: present for at least 3 years;
new-onset diabetes: variably defined as less than 1-3 years;
rapidly-deteriorating diabetes: sudden worsening of chronic, stable diabetes.
Each situation begs the question, “Which came first, diabetes or pancreatic cancer?” Aside from the fact that both diseases occur in the same organ, there is not a priori reason that one should directly impact the other."
I guess the Iran Deal recertification event was already factored in...
My household has almost 10 Apple products. Everyone I know has at least two Apple products. Everyone I know who has switched to an Android phone jumped right back on the Apple bandwagon within 30 days. $AAPL is the greatest consumer goods company in the world.
CiaB for pancreatic cancer in 2017:
Jan 4, 2017: $PMCB Announces pre-IND meeting with FDA
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) on Tuesday, January 17, 2017. The meeting is to discuss numerous aspects of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
For those who aren't familiar with the clinical trial process and the development of a therapy for pancreatic cancer, why is it important to have an experienced team surrounding PharmaCyte's technology heading into its clinical trial?
Dr. Manuel Hidalgo: “I cannot emphasize enough how important having an experienced team is to conducting any clinical trial, but even more a trial with a new technology like Cell in a Box®. Elements of an experienced team range from proper patient selection to the delivery of the treatment and monitoring safety and efficacy. Each one of these elements, just to name a few, requires careful attention to details, proper documentation and communication. As this is a new technology and is a non-conventional one, these details become even more important. This is like a performance. The sheet music (protocol) is important but the conductor (investigator) and the orchestra (research team) are also critical.”
The Chief Executive Officer of PharmaCyte explained retention of Facet, “After we completed much of the Chemistry, Manufacturing and Control (CMC) work for PharmaCyte’s pre-IND submission to the FDA, we decided that PharmaCyte needed to retain a life sciences consulting firm that could guide it in a broad spectrum of areas that will be required for the successful development of PharmaCyte’s therapy for pancreatic cancer.
“Facet’s initial efforts to date have included assembling all of the preclinical and clinical data available on PharmaCyte’s therapy for pancreatic cancer and submission to the FDA as a ‘pre-IND package.’ Subsequently, Facet made arrangements with the FDA for the pre-IND meeting with the FDA and played a significant role in the meeting. We are extremely pleased with Facet’s performance and are convinced, based upon the results of the FDA meeting, that we made the right selection in retaining Facet.”
In the company’s upcoming trial, the comparator arm that PharmaCyte’s pancreatic cancer therapy will be compared to is the combination of the cancer drug 5-fluorouracil (FU) and the compound leucovorin (LV). The necessary and quick decision was made by Dr. Manuel Hidalgo, the Principal Investigator for the upcoming clinical, Dr. Daniel Von Hoff with Translational Drug Development (TD2), the CRO for PharmaCyte’s clinical trial, and Dr. Matthias Löhr, the Chairman of PharmaCyte’s Medical and Scientific Advisory Board.
TD2 has been involved in many clinical trials. What are your early impressions of PharmaCyte's pancreatic cancer therapy?
Dr. Stephen Gately: “New and effective therapies for patients with pancreas cancer are clearly needed. We have reviewed PharmaCyte’s prior human clinical data and are encouraged that this approach may provide clinical benefit for patients with pancreas cancer. TD2 is grateful for the opportunity to work with PharmaCyte’s team on this exciting project.”
PharmaCyte does not plan to publish a date for the filing of its IND. At the current time, it’s extremely difficult for the company to supply a development timeline that will accurately predict when the IND will be filed. It would be irresponsible of the company to release what, at this point, would be a “hopeful” date for filing the IND. This date could change from day-to-day and week-to-week based upon several unforeseen variables – many of which are beyond PharmaCyte’s control. This means that we cannot give an accurate timeline for filing the IND because we too are awaiting a list of items to be completed by others.
“An IND encompasses many things, dealing with the manufacture and characterization of the product candidate, the clinical study design and nonclinical studies. PharmaCyte’s therapy for pancreas cancer has undergone or been part of several studies, so incorporation of that information into the IND is not ‘rate limiting’ or ‘slowing down the progress towards submitting an IND.’ The clinical study design that PharmaCyte agreed to undertake after meeting with the FDA is currently being drafted. This is also not rate limiting. To conduct the clinical trial, PharmaCyte will need to manufacture, test and release a Master Cell Bank, a Working Cell Bank and the encapsulated live cells. This information is also required to be described and documented in detail in the IND. The manufacture of these items is the rate limiting factor involved in submitting the IND.”
“Before the IND is filed, the following items must be available for inclusion:
(a) Documentation of preclinical work done on the cells.
(b) Toxicology studies.
(c) Documentation of preclinical work done on the capsules themselves.
(d) A wide array of CMC (Chemistry, Manufacturing and Controls) documentation that verifies that the final biologic product (the encapsulated cells) has been produced under current Good Manufacturing Practices (cGMP)-compliant conditions.
(e) Labeling for the final investigational biologic product.
(f) Previous evidence of human experience with the pancreas cancer therapy (low-dose ifosfamide plus Cell-in-a-Box® encapsulated genetically modified human cells).
(h) The Investigator’s Brochure.
(i) The Informed Consent Form
(j) The Case Report Form”
debenture paid via stock
Are you going to explain this comment? I mean, I've been out of college for a while, but back in the day Equity was equity and Debt was debt.
What is this "debenture paid via stock"?
Jan 4, 2017: $PMCB Announces pre-IND meeting with FDA
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) on Tuesday, January 17, 2017. The meeting is to discuss numerous aspects of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
For those who aren't familiar with the clinical trial process and the development of a therapy for pancreatic cancer, why is it important to have an experienced team surrounding PharmaCyte's technology heading into its clinical trial?
Dr. Manuel Hidalgo: “I cannot emphasize enough how important having an experienced team is to conducting any clinical trial, but even more a trial with a new technology like Cell in a Box®. Elements of an experienced team range from proper patient selection to the delivery of the treatment and monitoring safety and efficacy. Each one of these elements, just to name a few, requires careful attention to details, proper documentation and communication. As this is a new technology and is a non-conventional one, these details become even more important. This is like a performance. The sheet music (protocol) is important but the conductor (investigator) and the orchestra (research team) are also critical.”
The Chief Executive Officer of PharmaCyte explained retention of Facet, “After we completed much of the Chemistry, Manufacturing and Control (CMC) work for PharmaCyte’s pre-IND submission to the FDA, we decided that PharmaCyte needed to retain a life sciences consulting firm that could guide it in a broad spectrum of areas that will be required for the successful development of PharmaCyte’s therapy for pancreatic cancer.
“Facet’s initial efforts to date have included assembling all of the preclinical and clinical data available on PharmaCyte’s therapy for pancreatic cancer and submission to the FDA as a ‘pre-IND package.’ Subsequently, Facet made arrangements with the FDA for the pre-IND meeting with the FDA and played a significant role in the meeting. We are extremely pleased with Facet’s performance and are convinced, based upon the results of the FDA meeting, that we made the right selection in retaining Facet.”
In the company’s upcoming trial, the comparator arm that PharmaCyte’s pancreatic cancer therapy will be compared to is the combination of the cancer drug 5-fluorouracil (FU) and the compound leucovorin (LV). The necessary and quick decision was made by Dr. Manuel Hidalgo, the Principal Investigator for the upcoming clinical, Dr. Daniel Von Hoff with Translational Drug Development (TD2), the CRO for PharmaCyte’s clinical trial, and Dr. Matthias Löhr, the Chairman of PharmaCyte’s Medical and Scientific Advisory Board.
TD2 has been involved in many clinical trials. What are your early impressions of PharmaCyte's pancreatic cancer therapy?
Dr. Stephen Gately: “New and effective therapies for patients with pancreas cancer are clearly needed. We have reviewed PharmaCyte’s prior human clinical data and are encouraged that this approach may provide clinical benefit for patients with pancreas cancer. TD2 is grateful for the opportunity to work with PharmaCyte’s team on this exciting project.”
PharmaCyte does not plan to publish a date for the filing of its IND. At the current time, it’s extremely difficult for the company to supply a development timeline that will accurately predict when the IND will be filed. It would be irresponsible of the company to release what, at this point, would be a “hopeful” date for filing the IND. This date could change from day-to-day and week-to-week based upon several unforeseen variables – many of which are beyond PharmaCyte’s control. This means that we cannot give an accurate timeline for filing the IND because we too are awaiting a list of items to be completed by others.
“An IND encompasses many things, dealing with the manufacture and characterization of the product candidate, the clinical study design and nonclinical studies. PharmaCyte’s therapy for pancreas cancer has undergone or been part of several studies, so incorporation of that information into the IND is not ‘rate limiting’ or ‘slowing down the progress towards submitting an IND.’ The clinical study design that PharmaCyte agreed to undertake after meeting with the FDA is currently being drafted. This is also not rate limiting. To conduct the clinical trial, PharmaCyte will need to manufacture, test and release a Master Cell Bank, a Working Cell Bank and the encapsulated live cells. This information is also required to be described and documented in detail in the IND. The manufacture of these items is the rate limiting factor involved in submitting the IND.”
“Before the IND is filed, the following items must be available for inclusion:
(a) Documentation of preclinical work done on the cells.
(b) Toxicology studies.
(c) Documentation of preclinical work done on the capsules themselves.
(d) A wide array of CMC (Chemistry, Manufacturing and Controls) documentation that verifies that the final biologic product (the encapsulated cells) has been produced under current Good Manufacturing Practices (cGMP)-compliant conditions.
(e) Labeling for the final investigational biologic product.
(f) Previous evidence of human experience with the pancreas cancer therapy (low-dose ifosfamide plus Cell-in-a-Box® encapsulated genetically modified human cells).
(h) The Investigator’s Brochure.
(i) The Informed Consent Form
(j) The Case Report Form”
IF you figure the company value right now is 50Mil, and if they used the entire shelf, the dilution would be a 50% decrease in current owners value.
This is the S-3 filed on 9/13:
http://ir.pharmacytebiotech.com/all-sec-filings/content/0001683168-17-002356/0001683168-17-002356.pdf
It is a 124 page PDF. Go to page 39 for the list of Exhibits. Notice which standard forms were actually filed by Pepper Hamilton. Exhibit 4.1 and 4.3. Forms of debentures. There is NO underwriting agreement. As filed, this S-3 is for a $50 Million debenture.
This is the Effective S-3 filed on 10/17:
http://ir.pharmacytebiotech.com/all-sec-filings/content/0001019687-14-003904/0001019687-14-003904.pdf
Exhibits start on page 34. Still no underwriting agreement. Could an underwriting agreement be filed via amendment? Yes. But right now, if $PMCB wanted to take raise funds from this shelf, it would be via a debenture.
On the surface, it's as plain as day. Dr. Tong is both and MD and an MBA. His appointment is head of Audit Committee. Who better to audit a biotech than someone with both an MD and an MBA?
The speculation is just fun. I can rest very easy at night with my position in a certain electric car company that starts with a "T", even though it has an absurd PE ratio, because it is backed by a Chinese investment company that is looking years down the road instead of just at the next quarter.
In the case of $PCMB the speculation is natural.
It is a fact that China now has more new cases of pancreatic cancer than the US:
Annual diagnoses and deaths of pancreatic cancer in China are now beyond the number of cases in the United States. GLOBOCAN 2012 estimates that cases in China account for 19.45% (65727/337872) of all newly diagnosed pancreatic cancer and 19.27% (63662/330391) of all deaths from pancreatic cancer worldwide.
One in three of world’s adults with diabetes is in China, WHO reports.
Prevalence of chronic disease among Chinese has risen more than ninefold in a generation, far faster than in rest of world, thanks to unhealthy lifestyles, population growth and ageing
either way it's definitely a win-win situation. this next year should be interesting.
My thoughts exactly!!!
I would love to see $PTOTF do a test for the NYPD in the New York City Subway system. The City Hall and Wall Street subway stops would be absolutely perfect places for demonstrations.
China China China
Everywhere I look today it's just China China China. $PMCB and Dr. Tong. Oil might soon be traded in Yuan instead of Dollars. Alibaba overtaking Amazon globally. Good grief!
China will compel Saudi Arabia to trade oil in the Chinese yuan, posing a threat to the U.S. dollar's status as the world's reserve currency. Carl Weinberg, chief economist and managing director at High Frequency Economics, told CNBC that Beijing stands to become the most dominant global player in oil demand since China usurped the U.S. as the "biggest oil importer on the planet.":
Saudi Arabia has "to pay attention to this because even as much as one or two years from now, Chinese demand will dwarf U.S. demand," Weinberg said.
"I believe that yuan pricing of oil is coming and as soon as the Saudis move to accept it — as the Chinese will compel them to do — then the rest of the oil market will move along with them."
Chinese e-commerce giant Alibaba is on track to overtake U.S. rival Amazon as the world's top cloud computing services firm, according to the Alibaba-owned South China Morning Post. Simon Hu, president of Alibaba Cloud, told the Hong Kong daily that China's vast domestic market and the Chinese government’s “Belt and Road Initiative” gives the company its confidence:
“We have taken on Amazon on all fronts as our benchmark over past three years. Some of our products have already exceeded theirs,” Hu told the South China Morning Post on the sidelines of the Alibaba Computing Conference in the Chinese city of Hangzhou, where the company is based.
“While market expansion needs to be step by step, the technical capabilities of Alibaba Cloud are as good as Amazon’s AWS,” said Hu. He had vowed in 2015 to “match or surpass Amazon in four years” in terms of customers, technology and worldwide scale.
Nice DD!!!
Gotta love alumni associations and gatherings! Great places to gain legitimate business connections.
Dr Tong has some intriguing healthcare connections in China. In a 2014 speaker bio, Dr Tong is noted as
"... an independent Director as well as Chairman of Business Development Committee of Shanghai CP Guojian Pharmaceutical, the largest bio-pharmaceutical manufacturer, as well as being the Chairman of Executive Management Committee of Shanghai Kedu Healthcare Group, one of the largest medical equipment distributor and third-party service provider in China, representing products from GE, Philips, Siemens, Kodak and the like."
http://bipasiaforum.com/en/speakers/2014/speakers_Raymond_Tong.html
Kedu Healthcare Group described in 2016:
"After over a decade of development, Kedu Healthcare has grown into the nation’s largest and the most professional service provider of medical equipment management. Kedu Healthcare owns a nationwide service network that consists of over 700 engineers, customer service staff and salespeople. In total, it has more than 1,200 employees in branches spread all over the country, providing medical equipment management services for over 10,000 hospitals and 1 million pieces of medical equipment."
http://www.am-sino.com/en/news/20160522474.html
Kedu sponsored a dinner for the Mayor of Vancouver in an economic trade mission just last month, on the 7th of September:
http://www.mayorofvancouver.ca/news/mayor-robertson-joins-vancouver-economic-commission-trade-mission-china
While pancreatic cancer rates are actually now higher in China than in the US, I suspect Dr. Tong is mainly interested in CiaB for the treatment of diabetes. I'd imagine that the Chinese government has seen the cost of managing diabetes just explode, and the government there is very forward thinking.
I know people will say it's a distraction, but I would love $PMCB to have the resources and funds to pursue pancreatic cancer and diabetes simultaneously. Much better to NOT be a one-trick pony in the biotech space.
Most places will freeze you out if they suspect you're counting. You won't be able to step foot in any casino if you get flagged.
Playing perfect strategy is legal, counting cards is not. Blackjack is way to stressful in my opinion. I've been yelled at by the person to my left for taking a card that would have busted the dealer.
Yeah, no thanks, mini-bac, craps or hold'em for me.
That's pretty funny. Reminds me of a guy I went to undergrad with who had a Porsche 911 and he could drop it off at other car dealers and "test drive" another sports car for about a week, as long as his 911 was with the dealer. Then there was this group of young women I met at a conference in NYC. They were all aspiring actresses who ate breakfast and lunch and sometimes dinner by attending open conferences.
Nice find!
I'm assuming he's an independent director. On Audit, it makes a lot of sense to have someone who is an MD and an MBA looking over a biotech. China connections are a bonus (mostly for Austrianova imo), biotech connections are another bonus. Solid choice!
My trading strategy on China: go Long MCD, KO, and PMCB!!!
As I understand it, a "skilled" video poker player may do better than a novice, but still it's a machine, and it's programmed to make sure the house wins most of the time. Paddock evidently kept elaborate calculations telling him when specific machines had last paid out bigtime. But at least in 2015, he made a lot of money on that. How? Granted, he spent a lot of his time in casinos. But still, is that unusual?
One of the wealthiest people I personally know goes to Vegas every year, sometimes several times a year, because he's incredibly frugal and he gets a free vacation. He just has to give the casino enough action and he gets comped for the entire trip.
This can be done if you play perfect strategy in blackjack, bet on don't pass in craps, bet on bank in mini-baccarat, and if you play perfect strategy in video poker. The house edge is almost nil in these situations, so as long as you have the bankroll to handle swings, you are getting free food, drinks, rooms, shows, even free flights.
Most people don't play perfect strategy in video poker because it's counter intuitive. Say you get king of hearts, queen of hearts, jack of hearts, ten of spades and ten of diamonds. 99% of people drop the hearts and keep the pair as it's a guaranteed payout. Wrong, you want to go for the royal straight flush in hearts.
Why ? Nobody reads them.
Based on trading volume, people are clearly reading the posts here. Keep posting!
All my MJ stocks are down this morning except for Aphria.
I know the majority of people come here to read, but I sure do wish we'd see more posts from level-headed investors.
Personally I'm weary of doing business in China. I know with the popularity of $BABA everyone wants to be doing business in China, but I will remain skeptical. This doctor was educated in Canada, however, so that's good in my book.
Dr. Tong actually has his Bachelors, a Masters, a PhD and of course his Doctor of Medicine degree, so it's:
Dr. Raymond C.F. Tong, MBA, PhD, MD.
Dr Raymond C. F. Tong, M.D., 56, is the Chief Executive Officer of Harmony Medical Inc, an Asian investment group active in the introduction and distribution of medical and healthcare products and services in China and the Asia. Dr. Tong obtained his medical degree from the University of Toronto.
Interesting choice for $PMCB's Audit Committee. Dr. Tong is an MD, that's always a plus for a biotech. He has strong ties to both Canada and China, which seems to help Austrianova more than PMCB in the long term.
Pancreatic Cancer is important to China:
Cancer is currently one of the most important public health problems in the world. Pancreatic cancer is a fatal disease with poor prognosis. As in most other countries, the health burden of pancreatic cancer in China is increasing, with annual mortality rates almost equal to incidence rates. The increasing trend of pancreatic cancer incidence is more significant in the rural areas than in the urban areas. Annual diagnoses and deaths of pancreatic cancer in China are now beyond the number of cases in the United States. GLOBOCAN 2012 estimates that cases in China account for 19.45% (65727/337872) of all newly diagnosed pancreatic cancer and 19.27% (63662/330391) of all deaths from pancreatic cancer worldwide. The population’s growing socioeconomic status contributes to the rapid increase of China’s proportional contribution to global rates. Here, we present an overview of control programs for pancreatic cancer in China focusing on prevention, early diagnosis and treatment. In addition, we describe key epidemiological, demographic, and socioeconomic differences between China and developed countries. Facts including no nationwide screening program for pancreatic cancer, delay in early detection resulting in a late stage at presentation, lack of awareness of pancreatic cancer in the Chinese population, and low investment compared with other cancer types by government have led to backwardness in China’s pancreatic cancer diagnosis and treatment. Finally, we suggest measures to improve health outcomes of pancreatic cancer patients in China.